First One fourth 2013 Highlights Achieved record consolidated revenue of $73.9 million, up 43 percent over the prior year quarter. Received FDA authorization for 2 ANDAs, Naphazoline Hydrochloride 0.025 percent with Pheniramine Maleate 0.3 percent and Clindamycin Phosphate Injection in 5 percent Dextrose premix in three strengths, with a combined IMS addressable market size of $90 million. Filed 4 ANDAs and completed the development on yet another 2 ANDAs with a combined annual IMS market size of around $640 million. Completed modernization and the 1st phase of capacity growth at the Company's Somerset, NJ ophthalmic manufacturing plant. Opened a fresh, 19,000 square feet research and development center in Vernon Hills, Illinois; designed to accommodate 35 to 40 ANDA filings each year and expand in to the advancement of specialty formulations such as carbapenems, hormones and oncolytics.Yet the USDA and the EPA are poised to allow the unregulated usage of these chemicals in conventional agriculture, much just as that the USDA decided to deregulate GM alfalfa back in early 2011 ( The dramatic upsurge in the use of 2,4-D and dicamba, and these herbicides’ known impacts on off-focus on crops threaten the survival of the specialty crop creation in the Midwest, said Steve Smith of Red Gold, an Indiana-based food processor. It’s time USDA, the stewards of American agriculture, stood and considered the cumulative impacts of all these crops up. There is still time to keep a comment of opposition to 2 also,4-D and dicamba in the Federal Register. The deadline for submission is April, 27, 2012:.. Actelion launches new 20 mcg/mL Ventavis formulation Actelion Pharmaceuticals US, Inc., today announced the first industrial sales of a new 20 microgram per milliliter formulation of Ventavis, for the treating New York Heart Association Class III and IV pulmonary arterial hypertension .